Purchase of PromethION 2 Solo

The Food and Drug Administration is forecasting the purchase of a PromethION 2 Solo instrument along with associated accessories to support the development of long read sequencing methods for metagenomic and other direct sequencing applications, specifically targeting contaminated nascent food samples. This acquisition is intended to enhance the agency’s capability to analyze complex microbial communities and identify pathogens or contaminants in food products with high precision and resolution, enabling more effective monitoring and safeguarding of the food supply chain. The instrument will be utilized in advanced laboratory settings to process challenging samples where traditional short read sequencing may fall short. The procurement is associated with NAICS code 334516, indicating categorization under the manufacturing of medical and dental instruments and supplies, and the contract is being managed by the FDA's acquisition team. The point of contact for program-related inquiries is the Hfp Acquisition Liaison, reachable via hfpacquisitions@fda.hhs.gov, while the Contracting Officer position remains undetermined as of the posting date of May 25, 2026. This opportunity is publicly listed for industry forecast and planning purposes but has not yet been solicited, and no set-aside status or geographic performance restrictions have been specified.